(Q37554954)

21 August 2017

Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics (English)

1 reference

Erratum to: Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics.

21 August 2017

1 reference

corrigendum / erratum

0 references

author name string

Yu Sunakawa

1

1 reference

21 August 2017

Junji Furuse

2

1 reference

21 August 2017

Takuji Okusaka

3

1 reference

21 August 2017

Masafumi Ikeda

4

1 reference

21 August 2017

Fumio Nagashima

5

1 reference

21 August 2017

Hideki Ueno

6

1 reference

21 August 2017

Shuichi Mitsunaga

7

1 reference

21 August 2017

Kensei Hashizume

8

1 reference

21 August 2017

Yuichiro Ito

9

1 reference

21 August 2017

Yasutsuna Sasaki

10

1 reference

21 August 2017

4 April 2013

1 reference

Investigational New Drugs

21 August 2017

1 reference

21 August 2017

32

1 reference

21 August 2017

1

1 reference

21 August 2017

104-112

1 reference

Creative Commons Attribution 2.0 Generic

21 August 2017

start time

4 April 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913857

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913857

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913857

Tumor-stromal cell interactions and opportunities for therapeutic intervention

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913857

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913857

A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913857

Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913857

Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis.

25 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913857

10.1007/S10637-013-9953-8

1 September 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference

21 August 2017

PubMed publication ID

23553067

1 reference